Figure 1.

Change in median levels of serum inflammatory markers over time in patients who received infliximab 3 mg/kg + MTX or placebo + MTX through week 14 with a crossover to infliximab 6 mg/kg + MTX for ICAM-1 (A), IL-6 (B), VEGF (C), MMP-3 (D), CRP (E), and IL-12p40 (F). MTX, methotrexate; ICAM-1, intracellular cell adhesion molecule-1; IL-6, interleukin-6; VEGF, vascular endothelial growth factor; MMP-3, matrix metalloproteinase-3; CRP, C-reactive protein; IL-12p40, interleukin 12.